Teva Pharmaceutical Industries Ltd.’s plan to switch patients to a longer-acting version of its Copaxone treatment suffered a setback as a U.S. court ruling gave the $4 billion drug less than a year of patent protection.
Pfizer Inc. , the world’s biggest drugmaker, leads a race against three rivals to sell the first new pill in a decade for rheumatoid arthritis, a joint disease treated by injected drugs with $12 billion in annual sales.
Surging commodity prices are prompting investors to put more cash back into metals, grains and energy, according to Kenmar Group, which expects funds under management to grow by about a third to $2 billion by next March.
Teva Pharmaceutical Industries Ltd. , the world’s biggest maker of generic drugs, sees opportunity in the U.S. health-care overhaul as more people gain insurance coverage in the company’s biggest market.
Pfizer Inc. and Bristol-Myers Squibb Co.’s experimental drug apixaban wasn’t safer or more effective than a standard treatment in stopping blood clots in the legs and lungs of patients after hospitalization, a study found.